Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity

We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platele...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 131; no. 6; pp. 508 - 513
Main Authors Shi, Rui, Ge, Lan, Zhou, Xin, Ji, Wen-Jie, Lu, Rui-Yi, Zhang, Ying-Ying, Zeng, Shan, Liu, Xing, Zhao, Ji-Hong, Zhang, Wen-Cheng, Jiang, Tie-Min, Li, Yu-Ming
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.06.2013
Subjects
PRI
PPI
UA
ADP
Cr
MFI
RBC
DBP
WBC
BMI
SBP
CCB
Ago
TB
TC
ARB
TG
PAG
PCI
CHD
Online AccessGet full text

Cover

Loading…
Abstract We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. All subjects were dichotomized according to PRI medians (normal-responders: PRI<56.5%, n=17 and low-responders: PRI>56.5%, n=16) and PAG medians (normal-responders: PAG<43%, n=17 and low-responders: PAG>43%, n=16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P=0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r=−0.403, P=0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P=0.028). The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.
AbstractList We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD).OBJECTIVESWe aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD).A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR.MATERIALS AND METHODSA total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR.All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028).RESULTSAll subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028).The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.CONCLUSIONSThe present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.
Abstract Objectives We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). Materials and Methods A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. Results All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders ( P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = − 0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity ( CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028). Conclusions The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.
We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028). The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.
We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. All subjects were dichotomized according to PRI medians (normal-responders: PRI<56.5%, n=17 and low-responders: PRI>56.5%, n=16) and PAG medians (normal-responders: PAG<43%, n=17 and low-responders: PAG>43%, n=16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P=0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r=−0.403, P=0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P=0.028). The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.
Author Liu, Xing
Zhao, Ji-Hong
Zhang, Wen-Cheng
Jiang, Tie-Min
Ge, Lan
Li, Yu-Ming
Ji, Wen-Jie
Lu, Rui-Yi
Zhou, Xin
Shi, Rui
Zeng, Shan
Zhang, Ying-Ying
Author_xml – sequence: 1
  givenname: Rui
  surname: Shi
  fullname: Shi, Rui
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 2
  givenname: Lan
  surname: Ge
  fullname: Ge, Lan
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 3
  givenname: Xin
  surname: Zhou
  fullname: Zhou, Xin
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 4
  givenname: Wen-Jie
  surname: Ji
  fullname: Ji, Wen-Jie
  organization: Departments of Respiratory and Critical Care Medicine, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 5
  givenname: Rui-Yi
  surname: Lu
  fullname: Lu, Rui-Yi
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 6
  givenname: Ying-Ying
  surname: Zhang
  fullname: Zhang, Ying-Ying
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 7
  givenname: Shan
  surname: Zeng
  fullname: Zeng, Shan
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 8
  givenname: Xing
  surname: Liu
  fullname: Liu, Xing
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 9
  givenname: Ji-Hong
  surname: Zhao
  fullname: Zhao, Ji-Hong
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 10
  givenname: Wen-Cheng
  surname: Zhang
  fullname: Zhang, Wen-Cheng
  organization: Department of Physiology and Pathophysiology, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 11
  givenname: Tie-Min
  surname: Jiang
  fullname: Jiang, Tie-Min
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
– sequence: 12
  givenname: Yu-Ming
  surname: Li
  fullname: Li, Yu-Ming
  email: cardiolab@gmail.com
  organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23498169$$D View this record in MEDLINE/PubMed
BookMark eNqNkt1rFDEUxYNU7Lb6L5R59GXG3GQ-QURp_SgUhKrPMXvnTjdrZjIm2er-92bZLoU-2D4Fwjm_5J5zT9jR5CZi7Ax4ARzqN-sirrwbPYVCcJAFFwWH6hlbQNt0uSgbccQWnJddLtuyPWYnIaw5hwa66gU7FrLsWqi7Bft5QehJB-qz2epIlmI2mutcCJnR3znxg3FTZkKmQ3BokqTP_pi4ylbmZpW5KUfrZtO7G0_2HpGQGM2tiduX7PmgbaBXd-cp-_Hp4_fzL_nV18-X5x-uciybNuadTD_rK75sKgFSUA_lICTnmEYYqkYgNumq1kDLqiZYAi913XMskWMn5CBP2es9d_bu94ZCVKMJSNbqidwmKJB13aapAJL07E66WY7Uq9mbUfutOqSSBG_3AvQuBE-DQhN1TEFEr41VwNWuBLVWhxLUrgTFhUolJHv9wH544VHj-72RUlC3hrwKaGhC6o0njKp35nHEuwcItGYyqO0v2lJYu42fUg0KVEgG9W23IrsNgZQ1bwX_P-ApP_gHit7P1Q
CitedBy_id crossref_primary_10_3389_fendo_2018_00002
crossref_primary_10_1007_s10557_022_07370_8
crossref_primary_10_1080_09537104_2022_2042236
crossref_primary_10_1093_eurheartj_ehy234
crossref_primary_10_1016_j_lfs_2015_04_016
crossref_primary_10_1155_2014_450814
crossref_primary_10_1155_2023_9322188
crossref_primary_10_3390_cells10123526
crossref_primary_10_3390_jcm11071763
crossref_primary_10_3390_jcm11226849
crossref_primary_10_1016_j_ijcard_2024_132073
crossref_primary_10_1161_JAHA_121_021129
crossref_primary_10_1177_03000605211016209
crossref_primary_10_1016_j_tcm_2019_08_005
crossref_primary_10_1161_CIRCRESAHA_117_305784
crossref_primary_10_3389_fphys_2021_658524
crossref_primary_10_1161_CIRCRESAHA_116_309303
crossref_primary_10_1161_CIRCRESAHA_114_305663
crossref_primary_10_1177_1076029617726600
crossref_primary_10_1155_2015_981841
crossref_primary_10_1111_ijlh_13261
crossref_primary_10_1055_s_0042_1760258
crossref_primary_10_1155_2015_682857
crossref_primary_10_3390_jpm11060508
crossref_primary_10_1055_s_0040_1718730
crossref_primary_10_15690_vramn1214
crossref_primary_10_3389_fphar_2022_811422
crossref_primary_10_1007_s11239_017_1537_6
crossref_primary_10_1111_eci_13149
crossref_primary_10_1080_15476286_2021_1885188
crossref_primary_10_3390_ijms21103477
crossref_primary_10_3390_ijms21176150
crossref_primary_10_1089_ars_2020_8139
crossref_primary_10_26442_00403660_2019_08_000389
crossref_primary_10_1007_s11239_013_1022_9
crossref_primary_10_1016_j_thromres_2017_07_011
crossref_primary_10_1080_09537104_2022_2042233
crossref_primary_10_1055_s_0041_1730375
crossref_primary_10_3390_ijerph14030301
crossref_primary_10_3390_ijms21082897
crossref_primary_10_2217_pgs_2019_0089
crossref_primary_10_1089_ars_2017_7289
crossref_primary_10_3390_genes16030312
crossref_primary_10_1038_s41598_020_63263_6
crossref_primary_10_1080_09537104_2019_1636019
crossref_primary_10_1055_s_0040_1718400
crossref_primary_10_3390_cells11040607
crossref_primary_10_1038_s41598_023_42868_7
crossref_primary_10_1038_s41598_017_01887_x
crossref_primary_10_3390_medicina61010162
crossref_primary_10_1160_TH13_11_0977
crossref_primary_10_3390_biology11050644
crossref_primary_10_1160_TH14_07_0622
crossref_primary_10_1161_CIRCRESAHA_117_306817
crossref_primary_10_1093_cvr_cvae138
crossref_primary_10_1111_jth_12788
crossref_primary_10_1186_s12933_022_01517_5
crossref_primary_10_1016_j_thromres_2018_03_021
crossref_primary_10_3389_fendo_2018_00074
crossref_primary_10_1002_prp2_751
crossref_primary_10_1007_s10557_019_06855_3
crossref_primary_10_1111_jth_14442
crossref_primary_10_3109_09537104_2014_974527
crossref_primary_10_1080_09537104_2023_2200860
crossref_primary_10_1097_MPH_0000000000002127
crossref_primary_10_3390_ijms232415645
crossref_primary_10_1080_09537104_2018_1475635
crossref_primary_10_1016_j_lfs_2020_117364
crossref_primary_10_3390_ijms23063301
crossref_primary_10_1016_j_thromres_2013_06_002
crossref_primary_10_1371_journal_pone_0122784
crossref_primary_10_3389_fcvm_2020_610561
crossref_primary_10_1055_a_1478_2105
crossref_primary_10_3390_ijms22094799
crossref_primary_10_1158_1535_7163_MCT_21_0050
crossref_primary_10_1016_j_thromres_2013_03_017
crossref_primary_10_3390_jcm11061484
crossref_primary_10_1155_2017_4080364
crossref_primary_10_1007_s10557_021_07229_4
crossref_primary_10_3389_fphys_2021_652579
Cites_doi 10.1146/annurev.cellbio.19.110701.155609
10.1038/nsmb.1651
10.1182/blood-2010-09-299719
10.1182/blood-2011-03-291971
10.1161/CIRCULATIONAHA.109.866533
10.1016/j.jcin.2010.12.009
10.1080/09537100802272634
10.1111/j.1538-7836.2011.04414.x
10.1161/CIRCULATIONAHA.106.682658
10.1093/eurheartj/ehr407
10.1111/j.1538-7836.2007.02656.x
10.1016/j.cell.2009.01.002
10.1111/j.1538-7836.2009.03700.x
10.1136/hrt.2011.227272
10.1111/j.1538-7836.2007.02609.x
10.1093/eurheartj/ehr236
10.1016/j.jacc.2012.03.056
10.1136/hrt.2010.220491
10.1146/annurev-biochem-060308-103103
10.1161/CIRCINTERVENTIONS.111.962555
10.1111/j.1538-7836.2005.01751.x
10.1016/j.ahj.2010.06.004
10.1016/j.jacc.2008.07.055
10.1038/nature09267
10.1111/j.1538-7836.2004.01063.x
10.1160/TH07-05-0324
10.1016/S0092-8674(04)00045-5
10.1111/j.1423-0410.2010.01333.x
10.1016/j.jacc.2008.05.054
10.1056/NEJMoa0809171
10.4244/51
10.1001/jama.2009.1232
10.1016/j.jacc.2012.06.004
ContentType Journal Article
Copyright 2013 Elsevier Ltd
Elsevier Ltd
Copyright © 2013 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2013 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2013 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.thromres.2013.02.015
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-2472
EndPage 513
ExternalDocumentID 23498169
10_1016_j_thromres_2013_02_015
S0049384813000820
1_s2_0_S0049384813000820
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEB
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
WUQ
X7M
Z5R
ZGI
~G-
0SF
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
NCXOZ
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c478t-93195d50b752132ed14f2300c049f572cc7d146a1eb56e1b104a6d0c4c0c923f3
IEDL.DBID .~1
ISSN 0049-3848
1879-2472
IngestDate Mon Jul 21 09:22:38 EDT 2025
Thu Apr 03 07:00:51 EDT 2025
Tue Jul 01 02:27:34 EDT 2025
Thu Apr 24 23:08:30 EDT 2025
Fri Feb 23 02:31:40 EST 2024
Sun Feb 23 10:19:19 EST 2025
Tue Aug 26 16:32:37 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords miRNAs
PRI
LVEF
PPI
cGMP
cAMP
UA
ADP
Cr
MFI
RBC
DBP
ACEI
real time PCR
WBC
BMI
SBP
VASP
CCB
NSTE-ACS
PGE1
Ago
3’UTR
Platelet function test
TB
Vasodilator-stimulated phosphoprotein
TC
ARB
TG
High on-treatment platelet reactivity
MiroRNAs
PAG
PCI
LDPs
Clopidogrel
CHD
microRNAs
red blood cells
vasodilator-stimulated phosphoprotein
systolic blood pressure
total cholesterol
left ventricular ejection fraction
percutaneous coronary intervention
diastolic blood pressure
prostaglandin E1
white blood cells
adenosine diphosphate
uric acid
argonaute
mean fluorescence intensity
body mass index
angiotensin-converting enzyme inhibitor
3’untranslated region
cyclic guanosine monophosphate
total bilirubin
leukocyte-depleted platelets
platelet aggregation
proton pump inhibitors
platelet reactivity index
creatinine
angiotensin receptor blockers
calcium channel blockers
triglycerides
cyclic adenosine monophosphate
real time polymerase chain reaction
coronary heart disease
non-ST-segment elevation acute coronary syndrome
Language English
License Copyright © 2013 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c478t-93195d50b752132ed14f2300c049f572cc7d146a1eb56e1b104a6d0c4c0c923f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 23498169
PQID 1366822311
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1366822311
pubmed_primary_23498169
crossref_citationtrail_10_1016_j_thromres_2013_02_015
crossref_primary_10_1016_j_thromres_2013_02_015
elsevier_sciencedirect_doi_10_1016_j_thromres_2013_02_015
elsevier_clinicalkeyesjournals_1_s2_0_S0049384813000820
elsevier_clinicalkey_doi_10_1016_j_thromres_2013_02_015
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-06-01
PublicationDateYYYYMMDD 2013-06-01
PublicationDate_xml – month: 06
  year: 2013
  text: 2013-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Thrombosis research
PublicationTitleAlternate Thromb Res
PublicationYear 2013
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Aleil, Ravanat, Cazenave, Rochoux, Heitz, Gachet (bb0070) 2005; 3
O'Connell, Zhao, Rao (bb0175) 2011; 118
Varenhorst, James, Erlinge, Braun, Brandt, Winters (bb0065) 2009; 157
Ungar, Hughson (bb0155) 2003; 19
Landry, Plante, Ouellet, Perron, Rousseau, Provost (bb0100) 2009; 16
Nagalla, Shaw, Kong, Kondkar, Edelstein, Ma (bb0125) 2011; 117
Tantry, Kereiakes, Gurbel (bb0035) 2011; 4
Kondkar, Bray, Leal, Nagalla, Liu, Jin (bb0105) 2010; 8
Hamm, Bassand, Agewall, Bax, Boersma, Bueno (bb0110) 2011; 32
LaValley (bb0135) 2008; 117
Bonello, Paganelli, Arpin-Bornet, Auquier, Sampol, Dignat-George (bb0055) 2007; 5
Blindt, Stellbrink, de Taeye, Muller, Kiefer, Yagmur (bb0075) 2007; 98
Sianos, Morel, Kappetein, Morice, Colombo, Dawkins (bb0130) 2005; 1
Oh, Park, Kang, Park, Na, Kang (bb0160) 2012; 98
Breet, van Werkum, Bouman, Kelder, Harmsze, Hackeng (bb0015) 2011; 97
Paniccia, Antonucci, Gori, Marcucci, Giglioli, Antoniucci (bb0150) 2007; 5
Schubert, Devine (bb0140) 2010; 99
Aradi, Komocsi, Vorobcsuk, Rideg, Tokes-Fuzesi, Magyarlaki (bb0010) 2010; 160
Silvain, Cayla, Hulot, Finzi, Kerneis, O'Connor (bb0050) 2012; 33
Guo, Ingolia, Weissman, Bartel (bb0085) 2010; 466
Bartel (bb0080) 2004; 116
Jneid, Anderson, Wright, Adams, Bridges, Casey (bb0005) 2012; 60
Zampetaki, Willeit, Tilling, Drozdov, Prokopi, Renard (bb0170) 2012; 60
Shuldiner, O'Connell, Bliden, Gandhi, Ryan, Horenstein (bb0025) 2009; 302
Siller-Matula, Panzer, Jilma (bb0060) 2008; 19
Mega, Close, Wiviott, Shen, Hockett, Brandt (bb0020) 2009; 360
Berger, Bhatt, Steinhubl, Shao, Steg, Montalescot (bb0040) 2009; 120
Fabian, Sonenberg, Filipowicz (bb0090) 2010; 79
Cuisset, Frere, Quilici, Barbou, Morange, Hovasse (bb0115) 2006; 4
Siller-Matula, Lang, Christ, Jilma (bb0030) 2008; 52
Cuisset, Cayla, Frere, Quilici, Poyet, Gaborit (bb0120) 2009; 5
Jeong, Tantry, Kim, Koh, Kwon, Park (bb0165) 2011; 4
Ang, Palakodeti, Khalid, Tsimikas, Idrees, Tran (bb0045) 2008; 52
Bartel (bb0095) 2009; 136
Fernando, Bassler, Habersberger, Sheffield, Sharma, Dart (bb0145) 2011; 9
Aleil (10.1016/j.thromres.2013.02.015_bb0070) 2005; 3
Sianos (10.1016/j.thromres.2013.02.015_bb0130) 2005; 1
Ang (10.1016/j.thromres.2013.02.015_bb0045) 2008; 52
Hamm (10.1016/j.thromres.2013.02.015_bb0110) 2011; 32
O'Connell (10.1016/j.thromres.2013.02.015_bb0175) 2011; 118
Ungar (10.1016/j.thromres.2013.02.015_bb0155) 2003; 19
Varenhorst (10.1016/j.thromres.2013.02.015_bb0065) 2009; 157
Landry (10.1016/j.thromres.2013.02.015_bb0100) 2009; 16
Paniccia (10.1016/j.thromres.2013.02.015_bb0150) 2007; 5
LaValley (10.1016/j.thromres.2013.02.015_bb0135) 2008; 117
Jeong (10.1016/j.thromres.2013.02.015_bb0165) 2011; 4
Fernando (10.1016/j.thromres.2013.02.015_bb0145) 2011; 9
Siller-Matula (10.1016/j.thromres.2013.02.015_bb0060) 2008; 19
Zampetaki (10.1016/j.thromres.2013.02.015_bb0170) 2012; 60
Shuldiner (10.1016/j.thromres.2013.02.015_bb0025) 2009; 302
Siller-Matula (10.1016/j.thromres.2013.02.015_bb0030) 2008; 52
Aradi (10.1016/j.thromres.2013.02.015_bb0010) 2010; 160
Mega (10.1016/j.thromres.2013.02.015_bb0020) 2009; 360
Nagalla (10.1016/j.thromres.2013.02.015_bb0125) 2011; 117
Guo (10.1016/j.thromres.2013.02.015_bb0085) 2010; 466
Breet (10.1016/j.thromres.2013.02.015_bb0015) 2011; 97
Kondkar (10.1016/j.thromres.2013.02.015_bb0105) 2010; 8
Cuisset (10.1016/j.thromres.2013.02.015_bb0115) 2006; 4
Blindt (10.1016/j.thromres.2013.02.015_bb0075) 2007; 98
Schubert (10.1016/j.thromres.2013.02.015_bb0140) 2010; 99
Cuisset (10.1016/j.thromres.2013.02.015_bb0120) 2009; 5
Berger (10.1016/j.thromres.2013.02.015_bb0040) 2009; 120
Fabian (10.1016/j.thromres.2013.02.015_bb0090) 2010; 79
Silvain (10.1016/j.thromres.2013.02.015_bb0050) 2012; 33
Jneid (10.1016/j.thromres.2013.02.015_bb0005) 2012; 60
Tantry (10.1016/j.thromres.2013.02.015_bb0035) 2011; 4
Bartel (10.1016/j.thromres.2013.02.015_bb0080) 2004; 116
Bartel (10.1016/j.thromres.2013.02.015_bb0095) 2009; 136
Bonello (10.1016/j.thromres.2013.02.015_bb0055) 2007; 5
Oh (10.1016/j.thromres.2013.02.015_bb0160) 2012; 98
23597855 - Thromb Res. 2013 Jun;131(6):472-3
References_xml – volume: 32
  start-page: 2999
  year: 2011
  end-page: 3054
  ident: bb0110
  article-title: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
  publication-title: Eur Heart J
– volume: 19
  start-page: 493
  year: 2003
  end-page: 517
  ident: bb0155
  article-title: SNARE protein structure and function
  publication-title: Annu Rev Cell Dev Biol
– volume: 157
  start-page: e561
  year: 2009
  end-page: e569
  ident: bb0065
  article-title: Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
  publication-title: Am Heart J
– volume: 98
  start-page: 1329
  year: 2007
  end-page: 1334
  ident: bb0075
  article-title: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
  publication-title: Thromb Haemost
– volume: 52
  start-page: 1052
  year: 2008
  end-page: 1059
  ident: bb0045
  article-title: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel
  publication-title: J Am Coll Cardiol
– volume: 4
  start-page: 542
  year: 2006
  end-page: 549
  ident: bb0115
  article-title: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
  publication-title: J Thromb Haemost
– volume: 5
  start-page: 325
  year: 2009
  end-page: 329
  ident: bb0120
  article-title: Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
  publication-title: EuroIntervention
– volume: 117
  start-page: 5189
  year: 2011
  end-page: 5197
  ident: bb0125
  article-title: Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity
  publication-title: Blood
– volume: 5
  start-page: 1630
  year: 2007
  end-page: 1636
  ident: bb0055
  article-title: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
  publication-title: J Thromb Haemost
– volume: 4
  start-page: 585
  year: 2011
  end-page: 594
  ident: bb0165
  article-title: Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin
  publication-title: Circ Cardiovasc Interv
– volume: 60
  start-page: 290
  year: 2012
  end-page: 299
  ident: bb0170
  article-title: Prospective study on circulating MicroRNAs and risk of myocardial infarction
  publication-title: J Am Coll Cardiol
– volume: 3
  start-page: 85
  year: 2005
  end-page: 92
  ident: bb0070
  article-title: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
  publication-title: J Thromb Haemost
– volume: 33
  start-page: 1241
  year: 2012
  end-page: 1249
  ident: bb0050
  article-title: High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
  publication-title: Eur Heart J
– volume: 97
  start-page: 983
  year: 2011
  end-page: 990
  ident: bb0015
  article-title: High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
  publication-title: Heart
– volume: 19
  start-page: 551
  year: 2008
  end-page: 554
  ident: bb0060
  article-title: Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay
  publication-title: Platelets
– volume: 60
  start-page: 645
  year: 2012
  end-page: 681
  ident: bb0005
  article-title: 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
  publication-title: J Am Coll Cardiol
– volume: 136
  start-page: 215
  year: 2009
  end-page: 233
  ident: bb0095
  article-title: MicroRNAs: target recognition and regulatory functions
  publication-title: Cell
– volume: 9
  start-page: 1582
  year: 2011
  end-page: 1589
  ident: bb0145
  article-title: Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel
  publication-title: J Thromb Haemost
– volume: 5
  start-page: 1839
  year: 2007
  end-page: 1847
  ident: bb0150
  article-title: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients
  publication-title: J Thromb Haemost
– volume: 120
  start-page: 2337
  year: 2009
  end-page: 2344
  ident: bb0040
  article-title: Smoking, clopidogrel, and mortality in patients with established cardiovascular disease
  publication-title: Circulation
– volume: 16
  start-page: 961
  year: 2009
  end-page: 966
  ident: bb0100
  article-title: Existence of a microRNA pathway in anucleate platelets
  publication-title: Nat Struct Mol Biol
– volume: 118
  start-page: 2960
  year: 2011
  end-page: 2969
  ident: bb0175
  article-title: MicroRNA function in myeloid biology
  publication-title: Blood
– volume: 116
  start-page: 281
  year: 2004
  end-page: 297
  ident: bb0080
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
– volume: 360
  start-page: 354
  year: 2009
  end-page: 362
  ident: bb0020
  article-title: Cytochrome p-450 polymorphisms and response to clopidogrel
  publication-title: N Engl J Med
– volume: 117
  start-page: 2395
  year: 2008
  end-page: 2399
  ident: bb0135
  article-title: Logistic regression
  publication-title: Circulation
– volume: 160
  start-page: 543
  year: 2010
  end-page: 551
  ident: bb0010
  article-title: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis
  publication-title: Am Heart J
– volume: 302
  start-page: 849
  year: 2009
  end-page: 857
  ident: bb0025
  article-title: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
  publication-title: JAMA
– volume: 99
  start-page: 112
  year: 2010
  end-page: 122
  ident: bb0140
  article-title: De novo protein synthesis in mature platelets: a consideration for transfusion medicine
  publication-title: Vox Sang
– volume: 8
  start-page: 369
  year: 2010
  end-page: 378
  ident: bb0105
  article-title: VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA
  publication-title: J Thromb Haemost
– volume: 79
  start-page: 351
  year: 2010
  end-page: 379
  ident: bb0090
  article-title: Regulation of mRNA translation and stability by microRNAs
  publication-title: Annu Rev Biochem
– volume: 52
  start-page: 1557
  year: 2008
  end-page: 1563
  ident: bb0030
  article-title: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
  publication-title: J Am Coll Cardiol
– volume: 466
  start-page: 835
  year: 2010
  end-page: 840
  ident: bb0085
  article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels
  publication-title: Nature
– volume: 1
  start-page: 219
  year: 2005
  end-page: 227
  ident: bb0130
  article-title: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease
  publication-title: EuroIntervention
– volume: 98
  start-page: 139
  year: 2012
  end-page: 144
  ident: bb0160
  article-title: Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
  publication-title: Heart
– volume: 4
  start-page: 365
  year: 2011
  end-page: 380
  ident: bb0035
  article-title: Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations
  publication-title: JACC Cardiovasc Interv
– volume: 19
  start-page: 493
  year: 2003
  ident: 10.1016/j.thromres.2013.02.015_bb0155
  article-title: SNARE protein structure and function
  publication-title: Annu Rev Cell Dev Biol
  doi: 10.1146/annurev.cellbio.19.110701.155609
– volume: 16
  start-page: 961
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0100
  article-title: Existence of a microRNA pathway in anucleate platelets
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.1651
– volume: 117
  start-page: 5189
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0125
  article-title: Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity
  publication-title: Blood
  doi: 10.1182/blood-2010-09-299719
– volume: 118
  start-page: 2960
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0175
  article-title: MicroRNA function in myeloid biology
  publication-title: Blood
  doi: 10.1182/blood-2011-03-291971
– volume: 1
  start-page: 219
  year: 2005
  ident: 10.1016/j.thromres.2013.02.015_bb0130
  article-title: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease
  publication-title: EuroIntervention
– volume: 120
  start-page: 2337
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0040
  article-title: Smoking, clopidogrel, and mortality in patients with established cardiovascular disease
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.109.866533
– volume: 4
  start-page: 365
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0035
  article-title: Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations
  publication-title: JACC Cardiovasc Interv
  doi: 10.1016/j.jcin.2010.12.009
– volume: 19
  start-page: 551
  year: 2008
  ident: 10.1016/j.thromres.2013.02.015_bb0060
  article-title: Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay
  publication-title: Platelets
  doi: 10.1080/09537100802272634
– volume: 9
  start-page: 1582
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0145
  article-title: Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2011.04414.x
– volume: 117
  start-page: 2395
  year: 2008
  ident: 10.1016/j.thromres.2013.02.015_bb0135
  article-title: Logistic regression
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.106.682658
– volume: 33
  start-page: 1241
  year: 2012
  ident: 10.1016/j.thromres.2013.02.015_bb0050
  article-title: High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehr407
– volume: 5
  start-page: 1839
  year: 2007
  ident: 10.1016/j.thromres.2013.02.015_bb0150
  article-title: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2007.02656.x
– volume: 136
  start-page: 215
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0095
  article-title: MicroRNAs: target recognition and regulatory functions
  publication-title: Cell
  doi: 10.1016/j.cell.2009.01.002
– volume: 8
  start-page: 369
  year: 2010
  ident: 10.1016/j.thromres.2013.02.015_bb0105
  article-title: VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2009.03700.x
– volume: 98
  start-page: 139
  year: 2012
  ident: 10.1016/j.thromres.2013.02.015_bb0160
  article-title: Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
  publication-title: Heart
  doi: 10.1136/hrt.2011.227272
– volume: 5
  start-page: 1630
  year: 2007
  ident: 10.1016/j.thromres.2013.02.015_bb0055
  article-title: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2007.02609.x
– volume: 32
  start-page: 2999
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0110
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehr236
– volume: 60
  start-page: 290
  year: 2012
  ident: 10.1016/j.thromres.2013.02.015_bb0170
  article-title: Prospective study on circulating MicroRNAs and risk of myocardial infarction
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2012.03.056
– volume: 97
  start-page: 983
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0015
  article-title: High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
  publication-title: Heart
  doi: 10.1136/hrt.2010.220491
– volume: 79
  start-page: 351
  year: 2010
  ident: 10.1016/j.thromres.2013.02.015_bb0090
  article-title: Regulation of mRNA translation and stability by microRNAs
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev-biochem-060308-103103
– volume: 4
  start-page: 585
  year: 2011
  ident: 10.1016/j.thromres.2013.02.015_bb0165
  article-title: Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin
  publication-title: Circ Cardiovasc Interv
  doi: 10.1161/CIRCINTERVENTIONS.111.962555
– volume: 4
  start-page: 542
  year: 2006
  ident: 10.1016/j.thromres.2013.02.015_bb0115
  article-title: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2005.01751.x
– volume: 160
  start-page: 543
  year: 2010
  ident: 10.1016/j.thromres.2013.02.015_bb0010
  article-title: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2010.06.004
– volume: 52
  start-page: 1557
  year: 2008
  ident: 10.1016/j.thromres.2013.02.015_bb0030
  article-title: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.07.055
– volume: 466
  start-page: 835
  year: 2010
  ident: 10.1016/j.thromres.2013.02.015_bb0085
  article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels
  publication-title: Nature
  doi: 10.1038/nature09267
– volume: 3
  start-page: 85
  year: 2005
  ident: 10.1016/j.thromres.2013.02.015_bb0070
  article-title: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2004.01063.x
– volume: 98
  start-page: 1329
  year: 2007
  ident: 10.1016/j.thromres.2013.02.015_bb0075
  article-title: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
  publication-title: Thromb Haemost
  doi: 10.1160/TH07-05-0324
– volume: 116
  start-page: 281
  year: 2004
  ident: 10.1016/j.thromres.2013.02.015_bb0080
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
– volume: 99
  start-page: 112
  year: 2010
  ident: 10.1016/j.thromres.2013.02.015_bb0140
  article-title: De novo protein synthesis in mature platelets: a consideration for transfusion medicine
  publication-title: Vox Sang
  doi: 10.1111/j.1423-0410.2010.01333.x
– volume: 52
  start-page: 1052
  year: 2008
  ident: 10.1016/j.thromres.2013.02.015_bb0045
  article-title: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.05.054
– volume: 360
  start-page: 354
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0020
  article-title: Cytochrome p-450 polymorphisms and response to clopidogrel
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0809171
– volume: 157
  start-page: e561
  issue: 562
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0065
  article-title: Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
  publication-title: Am Heart J
– volume: 5
  start-page: 325
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0120
  article-title: Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
  publication-title: EuroIntervention
  doi: 10.4244/51
– volume: 302
  start-page: 849
  year: 2009
  ident: 10.1016/j.thromres.2013.02.015_bb0025
  article-title: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
  publication-title: JAMA
  doi: 10.1001/jama.2009.1232
– volume: 60
  start-page: 645
  year: 2012
  ident: 10.1016/j.thromres.2013.02.015_bb0005
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2012.06.004
– reference: 23597855 - Thromb Res. 2013 Jun;131(6):472-3
SSID ssj0017195
Score 2.3854492
Snippet We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary...
Abstract Objectives We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 508
SubjectTerms Aged
Blood Platelets - drug effects
Blood Platelets - metabolism
Clopidogrel
Coronary Disease - drug therapy
Coronary Disease - genetics
Down-Regulation - drug effects
Female
Hematology, Oncology and Palliative Medicine
High on-treatment platelet reactivity
Humans
Male
MicroRNAs - genetics
Middle Aged
MiroRNAs
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Platelet function test
Platelet Function Tests
Ticlopidine - analogs & derivatives
Ticlopidine - pharmacology
Ticlopidine - therapeutic use
Vasodilator-stimulated phosphoprotein
Title Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0049384813000820
https://www.clinicalkey.es/playcontent/1-s2.0-S0049384813000820
https://dx.doi.org/10.1016/j.thromres.2013.02.015
https://www.ncbi.nlm.nih.gov/pubmed/23498169
https://www.proquest.com/docview/1366822311
Volume 131
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dSxwxEB9EQXwptdr22ioR-hov2U2ym0exlWuLPkgF3-LmY-Hk3Du6J_TJv93Jbvaq2FJpX0M-lpnJzG828wHw0TvmfGkZtbUsqbBaUbRymnorM1W52kodE4VPz9TkQny9lJdrcDzkwsSwyqT7e53eaes0Mk7UHC-m05jjK3Qeq8HnvSGLGeyiiFJ-eLcK8-AF130XA6FpnP0gS_j6MLYiuEG3NoZ45V3tztge9_cG6k8AtDNEJy_hRUKQ5Kj_yG1YC80r2DxNb-Q7cPWpQ4Jt8GQxQySJjCE303OKFpqEnynutSHTllSJNTgz_o4lsXQxmTfUxSwqP0dPfPZrC9zS9Z0mduHi5PP34wlNfRSoE0W5pBqvmfSS2QJtdZ4Fz0WNngdzSJNaFplzBQ6pigcrVeAWPbRKeeYE8hHxX52_hvVm3oS3QALjQQjhEVgg9GC-lDhNh9IXvHZWlSOQA_GMS0XGY6-LmRmiya7NQHQTiW5YZpDoIxiv1i36Mht_XVEMvDFDEimqPYOW4N9Whjbd3tZw0-JM80TCRqBXKx8J6bNOPRgEyOANjs8yVRPmt3harhTCtJzzEbzpJWtFgywXuuRKv_uPk9_DVtb38KCMf4D15Y_bsIdIamn3u6uyDxtHX75Nzu4BZsIeJQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NTgJeEOOzMMCT9mpqJ7YTP04bU_fRPqBN2puJPyJ16tKKdBJ_PufGKSA2geDV8tnRne_ud7HvDmDfO-Z8aRm1tSypsFpR9HKaeiszVbnaSh0ThSdTNb4Up1fyagsO-1yY-Kwy2f7Opq-tdRoZJW6OlrNZzPEVOo_V4PPOkT2A7VidSg5g--DkbDzdXCYUXHeNDISmkeCnROHrj7EbwQ1GtvGVV74u3xk75N7to-7DoGtfdPwUniQQSQ6679yBrdA8g4eTdE3-HL4crcFgGzxZzhFMomzIzewzRSdNwrf09LUhs5ZUSTo4M_6RJbF6MVk01MVEKr_AYHz-Ywlc0nXNJl7A5fGni8MxTa0UqBNFuaIaNU16yWyB7jrPgueixuCDOeRJLYvMuQKHVMWDlSpwi0FapTxzAkWJELDOX8KgWTThNZDAeBBCeMQWiD6YLyVO06H0Ba-dVeUQZM8841Kd8djuYm76B2XXpme6iUw3LDPI9CGMNnTLrtLGHymKXjamzyNFy2fQGfwbZWiTAreGmxZnmt8O2RD0hvKXc_pXu-71B8igEsebmaoJi1vcLVcKkVrO-RBedSdrw4MsF7rkSr_5j50_wKPxxeTcnJ9Mz97C46xr6UEZ34XB6utteIfAamXfJ8X5DiHdINY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+platelet+miR-223+expression+is+associated+with+high+on-clopidogrel+platelet+reactivity&rft.jtitle=Thrombosis+research&rft.au=Shi%2C+Rui&rft.au=Ge%2C+Lan&rft.au=Zhou%2C+Xin&rft.au=Ji%2C+Wen-Jie&rft.date=2013-06-01&rft.issn=0049-3848&rft.volume=131&rft.issue=6&rft.spage=508&rft.epage=513&rft_id=info:doi/10.1016%2Fj.thromres.2013.02.015&rft.externalDBID=ECK1-s2.0-S0049384813000820&rft.externalDocID=1_s2_0_S0049384813000820
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00493848%2FS0049384813X00088%2Fcov150h.gif